I have a question about this trial description I f
Post# of 157973
(Total Views: 171)
Posted On: 10/15/2025 7:11:52 PM
I have a question about this trial description I found at one of the trial sites. Requires a search for Leronlimab after going there.
(I couldn't get it to come up in search just now)
https://www.foxchase.org/clinical-care/clinic...als/search
I mainly noticed that patients are occasionally allowed to self inject at home.
Someone also speculated that the 166 week time-frame means they could have already approved the rollover protocol? Or is it just a boilerplate time frame
Here is an excerpt from the description:
""Your group for the dose of leronlimab will be assigned once you are enrolled in the trial.
You will take a once weekly dose (subcutaneous injection) of leronlimab in combination with trifluridine + tipiracil (LONSURF®/TAS-102) + bevacizumab until your cancer no longer responds or until you get unacceptable side effects.
Leronlimab will be injected weekly via a very thin needle slightly below the surface of your skin in your stomach, by the research staff or visiting nurse. After the completion of one full cycle (4 weeks) participants will have the option of administering leronlimab at home on Day 8 (week 2) and Day 22 (week 4) of each subsequent cycle either by self-administration or by a caregiver after being trained to do so by the study staff.
LONSURF®/TAS-102 is taken twice daily for 5 days each week, with 2 days off, for two weeks out of every 4 weeks. The dose of LONSURF®/TAS-102 will be 35mg/m2 (based on your body surface area)
Bevacizumab will be administered intravenously once every other week. The dose of bevacizumab will be 5mg/kg"
You will be in this research study for as long as you do not have serious side effects and your disease does not get worse, or up to 166 weeks."
(I couldn't get it to come up in search just now)
https://www.foxchase.org/clinical-care/clinic...als/search
I mainly noticed that patients are occasionally allowed to self inject at home.
Someone also speculated that the 166 week time-frame means they could have already approved the rollover protocol? Or is it just a boilerplate time frame
Here is an excerpt from the description:
""Your group for the dose of leronlimab will be assigned once you are enrolled in the trial.
You will take a once weekly dose (subcutaneous injection) of leronlimab in combination with trifluridine + tipiracil (LONSURF®/TAS-102) + bevacizumab until your cancer no longer responds or until you get unacceptable side effects.
Leronlimab will be injected weekly via a very thin needle slightly below the surface of your skin in your stomach, by the research staff or visiting nurse. After the completion of one full cycle (4 weeks) participants will have the option of administering leronlimab at home on Day 8 (week 2) and Day 22 (week 4) of each subsequent cycle either by self-administration or by a caregiver after being trained to do so by the study staff.
LONSURF®/TAS-102 is taken twice daily for 5 days each week, with 2 days off, for two weeks out of every 4 weeks. The dose of LONSURF®/TAS-102 will be 35mg/m2 (based on your body surface area)
Bevacizumab will be administered intravenously once every other week. The dose of bevacizumab will be 5mg/kg"
You will be in this research study for as long as you do not have serious side effects and your disease does not get worse, or up to 166 weeks."
(0)
(0)